|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Alkermes Inc: Premium Company Profile |
|
|
|
|
€ 396,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2007 |
Taille du document : |
52 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (5) |
|
|
|
| 52 pages | Mars 2001 | Anglais
|
|
|
| Main
focus: |
biotechnology,bioinformatics,bio informatics,...,...
|
| Research
focus: |
market size and estimates,market segmentation, |
| Geographic
focus: |
canada,united kingdom,usa,france |
| |
|
|
|
|
| 101 pages | Décembre 2005 | Anglais
|
|
|
| Main
focus: |
pesticides,biotechnology,biotech
|
| Research
focus: |
market definition,industry structure, |
| Geographic
focus: |
usa,mexico,japan,canada,china,uruguay,india,... |
| |
|
|
|
|
| 92 pages | Octobre 2004 | Anglais
|
|
|
| Main
focus: |
pesticides,biopesticide,biotechnology,biotech
|
| Research
focus: |
market definition,market outlook, |
| Geographic
focus: |
usa,japan,mexico,canada,croatia,france |
| |
|
|
|
|
| 271 pages | Juillet 2006 | Anglais
|
|
|
| Main
focus: |
biotechnology,biotech,biotech crops,bioinformatic,...,...
|
| Research
focus: |
competition analysis,market size and estimates, |
| Geographic
focus: |
france,united kingdom,hungary,czech republic,... |
| |
|
|
|
|
| 90 pages | Janvier 1998 | Anglais
|
|
|
| Main
focus: |
biotechnology,biotech,genetics,drug discovery,...
|
| Research
focus: |
competition analysis,market outlook, |
| Geographic
focus: |
usa,india,uruguay,chile,colombia,venezuela,... |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Drug Delivery Outlook to 2005 150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c |
795,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets 214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals. Mar |
795,00 €
|
| |
| |
Healthcare In Northern Ireland 52 pages | Mai 2000 |
The Northern Ireland Presentation Includes:- The Structure Of The Health Service In Northern Ireland- Total Expenditure On Health & Personal Social Services- Number Of Inpatient Beds, BY Area- Occ |
327,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium 240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years. Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Maximising the Drug Lifecycle 102 pages | Août 2001 |
Up to $100bn of the 2000 pharmaceutical market, including blockbuster drugs with combined sales of $34bn will be exposed to generic competition by 2005.Maximising The Drug Lifecycle provides a detaile |
955,00 €
|
| |
| |
The Pharmacogenomics Outlook 174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development. By identifying differenc |
955,00 €
|
| |
| |
Lifestyle Drugs Outlook to 2005 130 pages | Février 1999 |
Definition of lifestyle drugs : The disease, product and social characteristics that make a drug lifestyle drug. Epidemiology : The patient potential for lifestyle drugs such as sexual dysfuncti |
795,00 €
|
| |
| |
Pain Therapeutics: A Strategic Re-evaluation. 198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 121 pages | Juillet 1998 |
Which pricing strategies will enable your company to maximise profitability? As healthcare cost-containment intensifies and pricing freedom is eroded, the need to develop new strategies to mainta |
795,00 €
|
| |
| |
The Pharmaceutical Industry Online 88 pages | Juillet 2002 |
In the United States, eMarketer projects that business-to-business e-commerce trade will grow to $1.3 trillion by 2005, while online trade in the health car |
800,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Alkermes Inc: Premium Company Profile |
|
|
Introduction
Alkermes is a biotechnology company focused on drug development process from a patient-centric perspective, beginning with a thorough understanding of the challenges patients face on a day-to-day basis. The company's acquisition of Medisorb Technologies and Advanced Inhalation Research (AIR) in 1996 and 1996 have resulted Alkermes in emerging as strong player with proven proprietary technologies.
Scope
Contains corporate strategy, value chain presence and SWOT AnalysisProvides detailed business description, segment analysis, 5-year financial trends, key products and key competitorsIncludes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Alkermes develops innovative medicines based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases and improve patient's lives.
The company has two commercial products: Risperdal Consta (risperidone), a long-acting atypical antipsychotic medication for schizophrenia and Vivitrol (naltrexone for extended-release injectable suspension), the first and only once-monthly injectable medication for the treatment of alcohol dependence
Its product candidates include ALKS 29 for alcohol dependence, AIR Inhaled Insulin (AIR Insulin) for diabetes, Exenatide LAR for Type 2 diabetes and AIR PTH for Osteoporosis. It enters into collaborations with pharmaceutical and biotechnology companies to develop new product candidates based on existing drugs incorporating its technologies.
Reasons to Purchase
Access all the important information and analysis on the company in a single reportUnderstand company's strengths, weaknesses, opportunities and threats along with business strategy and value chainGain access to company's adjusted five year financial data along with key ratios and market capitalization
|
|
TABLE OF CONTENTS Overview 1 Catalyst 1 Summary 1 Company Structure 6 Company Overview and Key Facts 6 Business Description 7 History 8 Locations and Subsidiaries 11 Company Financials 12 Stock Market Performance 12 P&L 15 Balance Sheet 18 Cash Flow 18 Business Segment Performance 19 Products & Services 22 Marketed Products 22 Pipeline Products 23 Technologies 25 AC Forecast Product Sales 26 Competitors and Strategic Business Relationships 27 Key Competitors 27 Key Suppliers 27 Key Clients 28 Shareholding Structure 29 Strategy 30 Company View 30 Corporate Strategy 31 SWOT Analysis 32 Overview 32 Strengths 33 Weaknesses 34 Opportunities 35 Threats 36 Value Chain Analysis 37 Overview 37 Product Development 38 Manufacturing 39 Scorecard 40 Overview 40 Scorecard Analysis 41 Key Employees 42 List of Key Employees 42 Key Employee Biographies 43 Financial and Operational Overview 49 Financial and Operational Overview 49 APPENDIX 52 Ask the analyst 52 Datamonitor consulting 52 Disclaimer 52
TABLE OF FIGURES Figure 1: Alkermes - Operating Revenue/Cost Analysis, 2002-2007 ($ Mn) 16 Figure 2: Alkermes - Key Strategic Revenues, 2003-2007 ($ Mn) 21
TABLE OF TABLES Table 1: Alkermes - Key Facts 6 Table 2: Alkermes – Locations and Subsidiaries 11 Table 3: Alkermes - Year-End Share Price and Market Capitalization, 2002-2006 ($) 12 Table 4: Alkermes - Key Events Impacting Share Price Performance 13 Table 5: Alkermes - Operating Revenue/Cost Analysis, 2002-2007 ($ Mn) 15 Table 6: Alkermes - Operating Cost Ratio Analysis, 2002-2007 (% of total revenues) 17 Table 7: Alkermes - Balance Sheet, 2002-2006 ($ Mn) 18 Table 8: Alkermes – Cash Flow, 2002-2006 ($ Mn) 18 Table 9: Alkermes - Revenue Breakdown by Division, 2002-2007 ($ Mn) 19 Table 10: Alkermes - Marketed Products 22 Table 11: Alkermes - In-house Pipeline Products 23 Table 12: Alkermes - Collaboration Products 23 Table 13: Alkermes - Forecast Sales, 2006-2011 ($ Mn) 26 Table 14: Alkermes - Key Competitors 27 Table 15: Alkermes - Key Suppliers 28 Table 16: Alkermes - Key Clients 28 Table 17: Alkermes - Key Shareholders 29 Table 18: Alkermes - SWOT Analysis Summary 32 Table 19: Alkermes - Value Chain Analysis 38 Table 20: Alkermes - Scorecard 40 Table 21: Alkermes - Key Employees 42 Table 22: Alkermes - Financial and Operational Overview 50
|
|
|
PPLSEN
|
|
|
|
|